An independent panel of experts from the TGA’s Advisory Committee on Vaccines (ACV) and the Australian Technical Advisory Group on Immunisation (ATAGI) have reviewed the recent reports of 4 cases of anaphylaxis in Queensland in people who have received COVID-19 AstraZeneca.
Utilising the internationally-accepted Brighton Collaboration case definition, it has been concluded that only 1 of the 4 reported cases meets the criteria for anaphylaxis. Whilst the other adverse events reported are not classified as anaphylaxis, they may still represent allergic reactions or immediate stress responses and therefore close monitoring and follow up is warranted.
The findings of this review confirm that the incidence of anaphylaxis following receipt of COVID-19 AstraZeneca does not occur at a rate higher than that expected for any vaccine.
To see the full alert from the TGA please follow the link below: